Gen-Probe Incorporated, a leading player in the molecular diagnostics industry, is headquartered in the United States. Founded in 1983, the company has made significant strides in the development of innovative diagnostic solutions, particularly in the areas of infectious diseases and cancer. With a strong presence in North America and Europe, Gen-Probe is renowned for its proprietary nucleic acid testing technologies, which provide rapid and accurate results. Their core products, including the Aptima® and Prodesse® test systems, are distinguished by their sensitivity and specificity, setting industry standards. Recognised for its commitment to quality and innovation, Gen-Probe has achieved notable milestones, including FDA approvals and partnerships that enhance its market position. As a trusted name in diagnostics, Gen-Probe continues to advance healthcare through its cutting-edge solutions.
How does Gen-Probe Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Gen-Probe Incorporated's score of 61 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Gen-Probe Incorporated, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Hologic, Inc., which may influence its climate commitments and reporting practices. As part of its corporate family, Gen-Probe's climate initiatives and targets are likely aligned with those of Hologic, Inc. However, no specific reduction targets or climate pledges have been documented for Gen-Probe itself. The absence of data suggests that the company may still be developing its own emissions strategy or relying on the broader commitments of its parent organisation. In the context of industry standards, it is essential for companies like Gen-Probe to establish clear emissions reduction targets and report on their progress to enhance transparency and accountability in their climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
Gen-Probe Incorporated's Scope 3 emissions, which decreased by 10% last year and decreased by approximately 10% since 2020, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 61% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Gen-Probe Incorporated has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.